MX2010003462A - TRATAMIENTO DE SINTOMAS DE INFECCION DE LAS VIAS RESPIRATORIAS SUPERIORES Y BIENESTAR PSICOLOGICO CON ß-GLUCANO. - Google Patents

TRATAMIENTO DE SINTOMAS DE INFECCION DE LAS VIAS RESPIRATORIAS SUPERIORES Y BIENESTAR PSICOLOGICO CON ß-GLUCANO.

Info

Publication number
MX2010003462A
MX2010003462A MX2010003462A MX2010003462A MX2010003462A MX 2010003462 A MX2010003462 A MX 2010003462A MX 2010003462 A MX2010003462 A MX 2010003462A MX 2010003462 A MX2010003462 A MX 2010003462A MX 2010003462 A MX2010003462 A MX 2010003462A
Authority
MX
Mexico
Prior art keywords
respiratory tract
upper respiratory
tract infection
infection symptoms
psychological well
Prior art date
Application number
MX2010003462A
Other languages
English (en)
Other versions
MX340664B (es
Inventor
Donald Cox
Steven Talbot
Original Assignee
Biopolymer Engineering Inc Dba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopolymer Engineering Inc Dba filed Critical Biopolymer Engineering Inc Dba
Publication of MX2010003462A publication Critical patent/MX2010003462A/es
Publication of MX340664B publication Critical patent/MX340664B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se llevaron a cabo estudios que implican diseños controlados con placebo, doble ciegos, para evaluar el efecto de composiciones de beta glucano en infecciones de las vías respiratorias superiores y en el bienestar psicológico. En el transcurso de los periodos de presentación de informes de estos estudios, los sujetos que estaban en los grupos de tratamiento informaron de menores síntomas de URTI, mejor salud general y una evaluación psicológica más positiva con base en el estudio POMS.
MX2010003462A 2007-09-27 2008-09-29 TRATAMIENTO DE SINTOMAS DE INFECCION DE LAS VIAS RESPIRATORIAS SUPERIORES Y BIENESTAR PSICOLOGICO CON ß-GLUCANO. MX340664B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97573407P 2007-09-27 2007-09-27
PCT/US2008/011249 WO2009042230A1 (en) 2007-09-27 2008-09-29 ß-GLUCAN TREATMENT OF UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING

Publications (2)

Publication Number Publication Date
MX2010003462A true MX2010003462A (es) 2010-08-18
MX340664B MX340664B (es) 2016-07-20

Family

ID=40511769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003462A MX340664B (es) 2007-09-27 2008-09-29 TRATAMIENTO DE SINTOMAS DE INFECCION DE LAS VIAS RESPIRATORIAS SUPERIORES Y BIENESTAR PSICOLOGICO CON ß-GLUCANO.

Country Status (15)

Country Link
US (1) US20110112048A1 (es)
EP (2) EP2205250B1 (es)
JP (2) JP2010540531A (es)
KR (3) KR20160067982A (es)
CN (3) CN105326852B (es)
AU (1) AU2008305545B2 (es)
CA (1) CA2700922C (es)
CO (1) CO6321155A2 (es)
ES (2) ES2580159T3 (es)
HK (1) HK1166016A1 (es)
MX (1) MX340664B (es)
MY (1) MY156219A (es)
PL (1) PL3072518T3 (es)
TR (1) TR201807223T4 (es)
WO (1) WO2009042230A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK500492010A3 (sk) * 2010-11-06 2012-06-04 Pleuran, S.R.O. Use of beta-D-glucane for decreasing undesirable effect of depression of immune response to excessive physical strain
CN103783370B (zh) * 2014-02-12 2015-05-20 北京同仁堂健康药业股份有限公司 一种保护呼吸道和肺部的组合物
CN115153023B (zh) * 2014-07-02 2024-06-04 嘉康利公司 用于增强免疫的组合物和方法
CN106038582A (zh) * 2016-05-06 2016-10-26 云南大学 以树突状细胞相关c型植物凝集素‑1为靶点的抗抑郁症药物及其筛选方法
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
US11872257B2 (en) 2017-08-11 2024-01-16 Biocodex Saccharomyces boulardii for the treatment of mood disorders
CA3079933A1 (en) 2017-10-23 2019-05-02 Nutrileads B.V. Enzymatically hydrolysed pectic polysaccharides for treating or preventing infections
WO2019112418A1 (en) 2017-12-04 2019-06-13 Nutrileads B.V. Composition for use in the prevention or treatment of salmonellosis
US20220132902A1 (en) * 2020-08-12 2022-05-05 Pharmavite, Llc Prebiotic composition of pectin, beta-glucan, xylooligosaccharide and/or ashwagandha and a method of improving mood

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
EP0490995A1 (en) 1989-09-08 1992-06-24 Alpha Beta Technology Method for producing soluble glucans
AU647751B2 (en) * 1989-09-08 1994-03-31 Alpha-Beta Technology, Inc. Method for immune system activation
US5811542A (en) 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5223491A (en) 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
US5576015A (en) 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
US6130244A (en) * 1998-02-25 2000-10-10 Abbott Laboratories Product and method to reduce stress induced immune suppression
JP2002209598A (ja) * 2001-01-15 2002-07-30 Kirin Brewery Co Ltd 酵母由来可溶性多糖
US6939864B1 (en) * 2001-07-09 2005-09-06 Purdue Research Foundation Animal feed compositions and methods of using the same
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
KR20030087383A (ko) * 2002-05-08 2003-11-14 강상모 효모벽 추출물의 베타-글루칸을 이용한 건강증진 방법
DE202004013521U1 (de) * 2004-08-30 2006-01-05 Almapharm Christian F.A. Botzenhardt Gmbh + Co Präparat aus beta-Glucan und Nukleotid zur Verabreichung an Tiere
US20060084629A1 (en) * 2004-10-15 2006-04-20 Alvin Needleman Immune system activating formula composed of selected long chain polysaccharides from natural sources
JP2007190002A (ja) * 2006-01-16 2007-08-02 Elson Kk ストレス適応形成を促進させる機能性飲食品

Also Published As

Publication number Publication date
WO2009042230A1 (en) 2009-04-02
CN105326852B (zh) 2018-11-23
AU2008305545B2 (en) 2014-07-17
US20110112048A1 (en) 2011-05-12
CN102309503B (zh) 2013-11-20
EP3072518B1 (en) 2018-05-09
HK1166016A1 (en) 2012-10-19
CN101873860A (zh) 2010-10-27
CN105326852A (zh) 2016-02-17
KR20150064233A (ko) 2015-06-10
JP2015155475A (ja) 2015-08-27
KR20160067982A (ko) 2016-06-14
KR20100077175A (ko) 2010-07-07
ES2580159T3 (es) 2016-08-19
EP2205250A1 (en) 2010-07-14
MY156219A (en) 2016-01-29
CN102309503A (zh) 2012-01-11
JP6078105B2 (ja) 2017-02-08
ES2675942T3 (es) 2018-07-13
EP2205250B1 (en) 2016-05-04
CA2700922A1 (en) 2009-04-02
PL3072518T3 (pl) 2018-10-31
CO6321155A2 (es) 2011-09-20
JP2010540531A (ja) 2010-12-24
MX340664B (es) 2016-07-20
EP2205250A4 (en) 2011-04-06
AU2008305545A1 (en) 2009-04-02
TR201807223T4 (tr) 2018-06-21
EP3072518A1 (en) 2016-09-28
CA2700922C (en) 2016-07-05

Similar Documents

Publication Publication Date Title
MX2010003462A (es) TRATAMIENTO DE SINTOMAS DE INFECCION DE LAS VIAS RESPIRATORIAS SUPERIORES Y BIENESTAR PSICOLOGICO CON ß-GLUCANO.
MX353727B (es) Tratamiento de sinucleinopatias.
SG10201901259RA (en) Prebiotic formulations and methods of use
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
MX2007005587A (es) Nueva composicion para facilitar el parto humano.
NZ591312A (en) Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct
UA100551C2 (en) Synbiotic mixture
MX2009008825A (es) Nuevos metodos de terapia anticolinergica.
WO2010086746A3 (en) Compositions and methods of treating viral infections
PH12014501290A1 (en) Methods and products to diagnose and treat heatiness
MY158310A (en) Prevention and treatment of allergic diarrhoea
MX2010008280A (es) Composicion para estimular la actividad de celula asesina natural.
ZA200703441B (en) Coadministration of tigecycline and digoxin
UA108975C2 (uk) Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями
IL194353A0 (en) Lysobactin amides
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
FI20075861A0 (fi) Enteroviruksen käyttö taudin diagnostiikassa, hoidossa ja ehkäisyssä
MX2009011214A (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
Mouradian Gingival recession and grafting
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
UA46160U (en) Massage arm-chair
RU2010140179A (ru) Способ лечения пародонтита - способ иорданишвили
UA34817U (ru) Способ медицинской реабилитации больных с синдромом повышенной усталости на фоне хронического тонзиллита
Lu et al. Adequacy and Tolerability of Bowel Preparation by Klean-Prep for Colonoscopy in the Elderly

Legal Events

Date Code Title Description
FG Grant or registration